Next-wave metabolic peptide: dual incretin receptor pharmacology.
Also known as: LY3298176 · dual GIP/GLP-1 agonist
Part of the Metabolic & GLP-1 peptides cluster
Overview
Tirzepatide is an engineered dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist peptide. It is an approved prescription medicine in multiple jurisdictions and a major case study in multi-receptor peptide design.
Source & context
Biological / chemical source: Synthetic engineered peptide
Primary research or clinical context: Approved prescription medicine in many markets for T2D/weight management
Dual-agonist design
Unlike single GLP-1 agonists, tirzepatide was optimized to engage both GIP and GLP-1 receptors. Medicinal chemistry balanced potency, selectivity, and pharmacokinetics — including fatty-acid modification strategies related to longer-acting incretins.
Educational vs. research materials
Approved branded products are regulated medicines. Research-grade materials labeled tirzepatide online are not equivalent to pharmacy products and may be illegal to market for human use without authorization.
IP and enforcement context
Tirzepatide has been the subject of aggressive intellectual-property and anti-counterfeit actions in some markets. Educational pages should clearly separate science literacy from product solicitation claims.
FAQ about Tirzepatide
What is Tirzepatide?+
Tirzepatide is an engineered dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist peptide. It is an approved prescription medicine in multiple jurisdictions and a major case study in multi-receptor peptide design.
Is Tirzepatide an approved medicine?+
Tirzepatide: Approved prescription medicine in many markets for T2D/weight management. Always follow licensed medical guidance for approved products.
What is the typical length of Tirzepatide?+
Tirzepatide is commonly described as approximately 39 amino acids (Incretin dual agonist).
Related peptides
References & further reading
- 1.Wikipedia — Tirzepatide
- 2.PubChem — compound summary for Tirzepatide (CID 156588324)
- 3.Rosenstock et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet
- 4.Frías et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med
- 5.Ludvik et al. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet
- 6.Del Prato et al. (2021). Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet
- 7.Dahl et al. (2022). Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA
- 8.Rosenstock et al. (2023). Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial. JAMA
- 9.Jastreboff et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med
- 10.Garvey et al. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet
- 11.Wadden et al. (2023). Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med
- 12.Aronne et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA
- 13.Malhotra et al. (2024). Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med
- 14.Packer et al. (2025). Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med
- 15.Sattar et al. (2022). Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med
- 16.Zoungas et al. (2026). A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial. Lancet Diabetes Endocrinol
- 17.Frias et al. (2018). Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet
- 18.Coskun et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab
- 19.Willard et al. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight
- 20.Sun et al. (2022). Structural determinants of dual incretin receptor agonism by tirzepatide. Proc Natl Acad Sci U S A
- 21.Nauck et al. (2022). Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol
- 22.Bucheit et al. (2022). A Novel Dual Incretin Agent, Tirzepatide (LY3298176), for the Treatment of Type 2 Diabetes Mellitus and Cardiometabolic Health. J Cardiovasc Pharmacol